Company / Gross Margin
Amphstar Pharmaceuticals, Inc. Gross Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
49.5%
FY2025
5-year range
45.6% / 54.5%
FY2021-FY2025
Trend
-3.2%
vs FY2024
Sector context
#20 of 28
Health Care
What the data says
At 49.5%, Amphstar Pharmaceuticals, Inc.'s gross margin ranks #20 of 28 in the Health Care sector. Declined from 54.5% to 49.5% over the past 2 years.
Based on SEC 10-K filings.
49.5% in FY2025 with a 5-year CAGR of +8.5%.
Declined from 54.5% to 49.5% over the past 2 years.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- -0.4pp
- 5-Year Change
- +8.5pp
- 10-Year Change
- -
Sector benchmark
#20 of 28 in Health CareTop 71% of 28This company 49.5% Sector average 60.3%
▼
-18.0% below sector average
Key checks
Key Insights
- In FY2025, gross margin decreased 3.2% year-over-year.
- Currently 10.8pp below the Health Care sector average.
- Peak gross margin was recorded in FY2023.
- Lowest gross margin in the period was in FY2018.
Company context
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 49.5% | -3.2% |
| FY2024 | 51.1% | -6.3% |
| FY2023 | 54.5% | +9.3% |
| FY2022 | 49.9% | +9.3% |
| FY2021 | 45.6% | +11.4% |
| FY2020 | 41.0% | +0.1% |
| FY2019 | 40.9% | +12.7% |
| FY2018 | 36.3% | -3.6% |
| FY2017 | 37.7% | -7.7% |
| FY2016 | 40.8% | +32.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026